Mikhail Blagosklonny’s Journeys with Anti-aging Drug Paying Returns

Posted on

Mikhail Blagosklonny, a renowned scientist in cancer and aging, and his contributions in anti-aging drugs are paying greater returns in the recent years. The hyperfunction theory put forward by Blagosklonny in the 2000s became the basis of all the anti-aging research in the later years. Though it was ridiculed by other researchers in the initial years, now it is proving to be a significant milestone in the development of treating age related health problems. With hyperfunction theory, Blagosklonny explained that aging should be considered as the continuation of growth that is driven by some types of signaling pathways like TOR or Target of Rapamycin. Until then, it was believed that aging was a functional decline caused by random molecular damages – something that cannot be prevented.The TOR model predicted that rapamycin and other rapalogs could be used to prevent diseases and treat aging. It says that by using proper dosages and schedules, people can extend their healthy lifespan. Though it was ridiculed by many peer reviewers, it also predicted that five years from then, people would take it as granted. The current development shows that the prediction was accurate and fulfilled. Currently, Evirolimus – a rapamycin analog – ensures immunity in aging people and led to further research in anti-aging drugs. It should be noted that Novartis started working on “Youth Drug” that can delay the various effects of aging and provide better health for older adults. Altogether, the drug targets everything related to aging and ensures a comfortable and healthy condition in the later part of the life.

In 2006, rapamycin was approved as a drug to use for cancer, autoimmunity, metabolic disorders, cardiovascular diseases, age related diseases from osteoporosis to Alzheimer’s, and more. Interestingly, it is safe for daily use for several years and can rejuvenate immunity. By 2010, most of the predictions of the TOR-centric model was found to true. It should be noted that the theory put forward by Blagosklonny also predicts calorie-restriction-mimicking technic of rapalogs and its side effects. It is found that rapamycin can create starvation-like symptoms in some conditions. The induced state caused by rapamycin stops the complications of type II diabetes. The mTOR-centric model suggests the reversible insulin resistance by rapamycin can increase the longevity of humans as it can lead to decreased mTOR pathway signaling.

Mikhail Blagosklonny works with Roswell Park Cancer Institute as a professor of Oncology. He is associated with a number of journals and works as the editor-in-chief of Cell Cycle and Oncotarget. Blagosklonny is also the associate editor of the American Journal of Pathology, PLOS ONE, International Journal of Cancer, and Cancer Biology and Therapy. Apart from aging and cancer, he also researches from clinical investigations to cellular and molecular biology. Blagosklonny wrote more than 300 reviews, research articles, book chapters, and more. Mikhail earned his MD in Internal Medicine from the First Pavlov State Medical University, St. Petersburg. He continued there and earned a Ph.D. in Cardiology and Experimental Medicine. Blagosklonny started his career with New York Medical College as an associate professor of medicine. Later, he joined Ordway Research Institute as a senior scientist, before joining Roswell Park.You can also follow them on Twitter : https://twitter.com/oncotargetjrnl?lang=en